Last updated: March 1, 2026
What is the drug identified by NDC 00023-6498?
NDC 00023-6498 corresponds to Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated primarily for depression, generalized anxiety disorder, diabetic peripheral neuropathy, and fibromyalgia.
Current Market Landscape
Market Size and Growth Trends
- The global antidepressant market was valued at approximately USD 15 billion in 2021, with expected compound annual growth rate (CAGR) of 2-3% through 2028 (Market Data Forecast, 2022).
- Duloxetine accounts for an estimated 20-25% of this market segment, with drug sales around USD 3-4 billion annually in the U.S.
- Growth drivers include rising prevalence of depression and anxiety, increased awareness, and expanded indications.
Competitive Environment
- Main competitors: SSRIs (e.g., Prozac, Zoloft), other SNRIs (e.g., Effexor), and newer agents like vortioxetine.
- Patent status: Patent expired in most markets, leading to increased generics. The first generic entered the U.S. market in 2014.
- Generics: Multiple manufacturers produce duloxetine generics, exerting significant price pressure.
Regulatory Status
- FDA approval: 2004.
- Patent expiry: January 2014, with ongoing patent litigation, potentially delaying some generics.
- Market Access: Widely available through retail pharmacies; insurance coverage largely favors generics due to lower cost.
Price Trends and Projections
Current Pricing Landscape
| Product Type |
Price Range (per 30-day supply) |
Notes |
| Brand (Cymbalta) |
USD 600 - 900 |
Reduced significantly since patent expiry |
| Generic (Duloxetine) |
USD 50 - 150 |
Highly variable by manufacturer and dosage |
- Brand prices have declined by 70-80% since patent expiry.
- Generics dominate the market, with some pricing below USD 100 per month.
Price Projection Factors
- Market penetration of generics: Continued expansion will keep prices suppressed.
- New formulations or indications: Would increase prices, but no recent approvals.
- Policy shifts: Initiatives promoting biosimilars and generics may further drive price reductions.
- Supply chain dynamics: Raw material costs and manufacturing capacity can influence pricing.
Future Price Trends (Next 3-5 Years)
| Scenario |
Price Range (USD per 30-day supply) |
Rationale |
| Conservative (Market saturation) |
USD 50 - 100 |
High generic competition persists |
| Moderate (Innovation or regulation) |
USD 75 - 125 |
Possible biosimilar entry, minor price increases |
| Aggressive (Patent-driven resurgence) |
USD 100 - 200 |
Unlikely; patent expiries dominate trends |
- In markets like the U.S., pricing will stay within the lower end of the generics spectrum barring major regulatory or patent developments.
- Emerging markets may see higher prices due to lower competition and supply constraints.
Key Market Opportunities & Challenges
Opportunities
- Expanding indications, such as new psychiatric or neuropathic conditions.
- Biosimilar development for branded products, although duloxetine is not biologic.
- Digital health integration for dosing or monitoring adherence could enhance product value.
Challenges
- Entrenched generic competition limits pricing power.
- Healthcare policy initiatives aim to reduce drug prices further.
- Concerns around side effects and competitive alternatives could impact demand.
Conclusions
Duloxetine under NDC 00023-6498 has a mature market with predominantly generic competition. Prices have stabilized at low levels, with projections favoring continued pricing pressure. Industry dynamics emphasize cost-conscious prescribing, particularly in managed care settings.
Key Takeaways
- The current price range for generic duloxetine is USD 50-150 per 30-day supply, with downward pressure expected.
- Brand prices have decreased significantly since patent expiry, now often exceeding USD 600 annually.
- Patent protections and regulatory delays are unlikely to alter the near-term price landscape substantially.
- Market growth depends on expanding indications and regional penetration, but price decline remains the central theme.
- Future price increases are unlikely unless new formulations or indications emerge.
FAQs
1. What factors most influence duloxetine prices?
Patent status, generic competition, healthcare policy, and regional market dynamics.
2. How does the availability of generics affect the market?
Generics introduce pricing competition, driving prices downward and reducing margins for branded products.
3. Are there upcoming regulatory changes that could impact prices?
No known major regulatory shifts are expected in the near term; existing policies favor price reductions for generics.
4. What is the outlook for new indications or formulations?
Limited without new FDA approvals; current focus remains on existing approved uses.
5. How do pricing trends in the U.S. compare with other regions?
The U.S. exhibits lower prices for generics due to high competition, while emerging markets may maintain higher prices due to limited supply.
References
[1] Market Data Forecast. (2022). Global antidepressant market size and forecast.
[2] IQVIA. (2022). U.S. prescription drug market analysis.
[3] FDA. (2004). Approval letter for Cymbalta.
[4] GoodRx. (2023). Duloxetine (generic and brand) prices.
